Skip to content

US · VRAX · BIOTECHNOLOGY

Virax Biolabs Group Limited (VRAX) intrinsic value and stock valuation

$0.33as of 2026-11-21 · Mkt cap 543.08K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Virax Biolabs Group Limited DCF and intrinsic value

InvestorsCraft values VRAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VRAX’s statements →

Virax Biolabs Group Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lanarkshire, SC ML1 5UH viraxbiolabs.com

How the business is doing

Fiscal 2020–2026, USD

Revenue
$10K-39.2% 5y CAGRd
20202026
Net income
-$-5.02M
20202026
Free cash flow
-$-4.88M
20202026
Total equity
$7.33M
20202026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2026, USD
20262025202420232022
Revenue$10K$10K$160K$10K$0.00
Operating income-$-6.4M-$-6.16M-$-6.5M-$-5.73M-$-1.73M
Net income-$-5.02M-$-6.06M-$-6.73M-$-5.46M-$-1.71M
EPSd-$-12.55M-$-50.5M-$-84.13M-$-136.5M-$-34.2M
Operating cash flow-$-4.62M-$-4.56M-$-6.25M-$-4.18M-$-810K
Capital expenditure-$-260K-$-600K-$-1.16M-$-180K$0.00
Free cash flow-$-4.88M-$-5.17M-$-7.41M-$-4.36M-$-810K
Total assets$8.32M$6.43M$5.48M$9.81M$50K
Total debt$410K$380K$220K$150K$0.00
Net debt-$-6.02M-$-3.85M-$-3.36M-$-9.21M-$-20K
Total equity$7.33M$5.46M$5.14M$8.9M-$-1.2M
Cash and short-term investments$6.52M$4.23M$3.59M$9.35M$20K
Income statement
20262025202420232022
Revenue$10K$10K$160K$10K$0.00
Cost of revenue$0.00$60K$110K$10K$0.00
Gross profit$10K-$-50K$50K-$0.00$0.00
Research and development expenses$3.74M$1.78M$1.56M$400K$430K
Selling, general and administrative expenses$2.67M$4.33M$4.59M$5.33M$1.3M
Other expenses$0.00$0.00$390K$0.00$0.00
Operating expenses$6.41M$6.11M$6.55M$5.73M$1.73M
Cost and expenses$6.41M$6.17M$6.65M$5.74M$1.73M
Interest income$0.00$0.00$0.00$0.00$20K
Interest expense$60K$60K$30K$20K$20K
Depreciation and amortization$350K$340K$100K$0.00$1.73M
Ebitda-$-6.05M-$-5.8M-$-6.61M-$-5.44M-$0.00
Operating income-$-6.4M-$-6.16M-$-6.5M-$-5.73M-$-1.73M
Total other income/expenses, net$470K-$-40K-$-240K$270K-$-20K
Income before tax-$-5.93M-$-6.2M-$-6.74M-$-5.46M-$-1.75M
Income tax expense$900K-$-140K$0.00$0.00$0.00
Net income-$-5.02M-$-6.06M-$-6.73M-$-5.46M-$-1.71M
Weighted average shares outstanding$400K$120K$80K$40K$50K
Weighted average diluted shares outstanding$400K$120K$80K$40K$50K
Balance sheet
20262025202420232022
Cash and short-term investments$6.52M$4.23M$3.59M$9.35M$20K
Net receivables$0.00$30K$220K$0.00$0.00
Inventory$50K$90K$60K$20K$20K
Total current assets$6.83M$4.89M$4.38M$9.63M$50K
Property, plant and equipment, net$1.5M$1.53M$1.1M$0.00$0.00
Goodwill and intangible assets$0.00$40K$50K$180K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.5M$1.53M$1.1M$180K$0.00
Total assets$8.32M$6.43M$5.48M$9.81M$50K
Accounts payable$50K$60K$50K$160K$850K
Short-term debt$110K$90K$50K$150K$0.00
Deferred revenue$0.00$0.00$0.00$40K-$0.00
Total current liabilities$690K$670K$170K$910K$1.25M
Long-term debt$300K$290K$180K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$300K$290K$180K$0.00$0.00
Capital lease obligations$390K$340K$220K$0.00$0.00
Total liabilities$990K$960K$350K$910K$1.25M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-29.61M-$-24.59M-$-18.53M-$-11.79M-$-6.34M
Accumulated other comprehensive income (loss)$37.2M$30.3M$23.9M$20.9M$5.36M
Total equity$7.33M$5.46M$5.14M$8.9M-$-1.2M
Total investments$80K$0.00$0.00$0.00$0.00
Total debt$410K$380K$220K$150K$0.00
Net debt-$-6.02M-$-3.85M-$-3.36M-$-9.21M-$-20K
Cash flow statement
20262025202420232022
Net income-$-5.02M-$-6.07M-$-6.74M-$-5.46M-$-1.71M
Depreciation and amortization$440K$340K$100K$0.00$0.00
Stock-based compensation$130K$370K$1.01M$1.73M$290K
Change in working capital$270K$630K-$-1.12M-$-220K$640K
Accounts receivable$0.00$220K-$-220K$0.00$0.00
Inventory$90K-$-30K-$-60K$20K$0.00
Accounts payable$0.00$470K-$-570K$30K$640K
Net cash provided by operating activities-$-4.62M-$-4.56M-$-6.25M-$-4.18M-$-810K
Investments in property, plant and equipment-$-260K-$-600K-$-950K-$-180K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-260K-$-600K-$-1.16M-$-180K$0.00
Common stock issued$2.78M$5.13M$0.00$13.7M$520K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.09M$5.81M$1.65M$13.7M$810K
Net change in cash$2.21M$640K-$-5.76M$9.33M$0.00
Cash at end of period$6.44M$4.23M$3.59M$9.35M$20K
Operating cash flow-$-4.62M-$-4.56M-$-6.25M-$-4.18M-$-810K
Capital expenditure-$-260K-$-600K-$-1.16M-$-180K$0.00
Free cash flow-$-4.88M-$-5.17M-$-7.41M-$-4.36M-$-810K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Virax Biolabs Group Limited

        Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

        CEO
        James Foster
        Employees
        26
        Beta
        1.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Virax Biolabs Group Limited (VRAX)?

        InvestorsCraft does not currently publish an intrinsic value for VRAX. How the IC value is calculated.

        Is VRAX undervalued?

        InvestorsCraft does not publish an undervaluation signal for VRAX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.